Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –– Topline data for ...
Operating an in-house durable medical equipment (DME) program can increase both patient satisfaction and profitability. Sustainable, successful programs are built on a solid foundation that includes ...
– Phase 3 LUGANO and LUCIA clinical trials for DURAVYU ™ in wet AMD fully enrolled and on track for data readout beginning in mid-2026 – – Announced initiation of pivotal Phase 3 DME program ...
President and Chief Executive Officer — Jay S. Duker, M.D. Chief Financial Officer — George O. Elston Chief Medical Officer — Ramiro Ribeiro, M.D. Management expects DuraVu to be the only tyrosine ...
The Centers for Medicare & Medicaid Services has responded to a challenge to provide savings information on a competitive bidding process it's implementing for durable medical equipment. On Friday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results